FSHD Society, C-Path Gathering Trial Data on Placebo Group Patients
The FSHD Society has joined forces with the Critical Path Institute (C-Path) to facilitate the collection of data from people with facioscapulohumeral muscular dystrophy (FSHD) who were given a placebo in previous clinical trials. Provided by sponsors of FSHD trials, the data will be integrated into C-Path’s Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP), …
FSHD Society, C-Path Gathering Trial Data on Placebo Group Patients Read More »